Hikma Strikes $185m Deal For Xellia Injectables Portfolio, Manufacturing Facility
Investment In Ohio Facility Will Allow In-House Production For Xellia Injectables
Hikma is not resting on its laurels after paying $375m upfront for US injectables specialist Custopharm two years ago, penning another acquisition agreement for a bundle of pharma and physical assets from Danish firm Xellia.
